Fulcrum Therapeutics Inc. (FULC) Tops Q4 EPS by 12c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. VRTX
4. CHKP
5. ON
6. CRWD
7. HNGE
8. INSP
9. SPY
10. MRVL

Go back to Fulcrum Therapeutics Inc. (FULC) Tops Q4 EPS by 12c

Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2019 Financial Results

March 5, 2020 7:01 AM EST

Conference call scheduled for 8:00 a.m. ET today

CAMBRIDGE, Mass., March 05, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update and reported financial results for the fourth quarter and full year of 2019.

We made important progress at a rapid pace in 2019 as we transitioned from a private, discovery company into a public, clinical-stage company, said Robert J. Gould, president and chief executive officer. In our losmapimod program for patients with... More